NBIX — Neurocrine Biosciences Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual balance sheet for Neurocrine Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	671	801	711	989	1,032
Net Total Accounts Receivable
Net Total Receivables	127	157	186	350	439
Total Inventory
Total Other Current Assets
Total Current Assets	831	1,016	973	1,454	1,607
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	116	127	156	146	347
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	1,306	1,735	2,073	2,369	3,251
Accounts Payable
Payable / Accrued
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	565	187	246	538	655
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	669	609	699	661	1,019
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	637	1,126	1,374	1,708	2,232
Total Liabilities & Shareholders' Equity	1,306	1,735	2,073	2,369	3,251
Total Common Shares Outstanding